1h Free Analyst Time
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Oncology, Immunology, Dermatology, Gastrointestinal, Metabolic Disorders and Musculoskeletal Disorders which include indications Alzheimer's Disease, Down Syndrome, Glioblastoma Multiforme (GBM), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Colon Cancer, Depression, Inflammatory Bowel Disease, Knee Osteoarthritis, Lung Cancer, Osteoarthritis, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Psoriasis, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
The latest report Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H2 2019, outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
- The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Avanti Biosciences Inc
Carna Biosciences Inc
Felicitex Therapeutics Inc
KinoPharma Inc
ManRos Therapeutics
NeuroNascent Inc
Pharmasum Therapeutics AS
Samumed LLC
San Biotechnology Co Ltd
Voronoi
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles
ABI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYR-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-1610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-7742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-8553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-9847 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPO-1143 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorecivivint - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-07883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate DYRK1A for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Parkinson's Disease and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRN-024219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Nov 13, 2019: Samumed presents safety data analysis of lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Jul 18, 2019: Samumed announces publication of preclinical data demonstrating that SM07883 is a potential treatment for alzheimer’s disease
Jun 19, 2019: Samumed doses first subject in phase 3 STRIDES-X-ray trial of lorecivivint for the treatment of knee osteoarthritis
May 02, 2019: Samumed launches phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10, 2019: Samumed announces multiple presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 04, 2019: Samumed doses first subject in phase 1 trial of SM07883, a potential treatment for Alzheimer's Disease
Mar 07, 2019: Samumed to present clinical data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Feb 28, 2019: Samumed announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in knee osteoarthritis
Jan 29, 2019: Samumed to present novel biological targets of SM04690 for treatment of knee osteoarthritis
Nov 05, 2018: Samumed announces multiple presentations at 6th world congress on controversies, debates & consensus in bone, muscle & joint diseases.
Oct 24, 2018: Samumed phase 2b trial in knee osteoarthritis meets primary endpoints
Oct 18, 2018: Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress
Oct 16, 2018: Samumed to present data from phase 2b trial of SM04690 for treatment of knee osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer's Association International Conference
Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer's Disease Candidate, at the Alzheimer's Association International Conference 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avanti Biosciences Inc, H2 2019
Pipeline by Carna Biosciences Inc, H2 2019
Pipeline by Felicitex Therapeutics Inc, H2 2019
Pipeline by KinoPharma Inc, H2 2019
Pipeline by ManRos Therapeutics, H2 2019
Pipeline by NeuroNascent Inc, H2 2019
Pipeline by Pharmasum Therapeutics AS, H2 2019
Pipeline by Samumed LLC, H2 2019
Pipeline by San Biotechnology Co Ltd, H2 2019
Pipeline by Voronoi, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avanti Biosciences Inc
- Carna Biosciences Inc
- Felicitex Therapeutics Inc
- KinoPharma Inc
- ManRos Therapeutics
- NeuroNascent Inc
- Pharmasum Therapeutics AS
- Samumed LLC
- San Biotechnology Co Ltd
- Voronoi
